Anzu Partners, an investment firm, led a $14m round in ImmunoScape, a pre-clinical biotechnology company, with participation from Amgen Ventures and EDBI. “We have made significant strides in our discovery program and have identified several compelling clinical TCR candidates using our Deep Immunomics platform. The new funding will allow us to expedite our development efforts and help us to advance our therapeutic candidates toward the clinic. We are especially delighted that Amgen Ventures has become an investor and we look forward to working with their team to address important unmet medical needs with ImmunoScape’s technology," Choon Peng Ng, ImmunoScape CEO.